Clinical Evaluation of Roxithromycin 300mg Once a Day Administration in Acute Dental Infections. Comparative study using Cefaclor as the control drug.:—Comparative study using Cefaclor as the control drug—

概要

論文の詳細を見る
Once a day administration of 300mg roxithromycin (RXM) for treatment of acute dental infections was objectively evaluated in a controlled study using cefaclor (CCL) as the control drug. Patients received RXM at a daily dose of 300mg (once a day) or CCL at a daily dose of 1, 500mg (3times a day) . 36 cases in the RXM group and 30 cases in the CCL group were evaluated for efficacy. 1) The clinical efficacy rating according to the criteria for Antibiotic Efficacy Evaluation of the Japanese Association for Oral Surgery was 83.3% in the RXM group and 93.3% in the CCL group. Although the efficacy rating was 10.0% higher in the CCL group, no significant difference was observed between the two groups. 2) The clinical efficacy rating judged by the attending doctors was 83.4% in the RXM group and 83.3% in the CCL group ; no significant difference was observed between the two groups. 3) Side effects occurred in 1 out of 30 cases in the CCL group only, and there was no significant difference between the two groups. 4) The usefulness rating, based on clinical efficacy and side effects, was 91.6% in the RXM group and 83.3% in the CCL group, with no significant difference between the two groups. These results showed that 300mg RXM once a day administration was as effective as 500mg CCL three times a day in the treatment of acute dental infections.
日本歯科薬物療法学会の論文